• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Urdea Michael S acquired $460 worth of shares (2,872 units at $0.16), increasing direct ownership by 9% to 33,159 units (SEC Form 4)

    3/28/24 2:09:36 PM ET
    $PBIO
    Get the next $PBIO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Urdea Michael S

    (Last) (First) (Middle)
    100 BUNCE MEADOWS DRIVE

    (Street)
    ALAMO CA 94507

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PRESSURE BIOSCIENCES INC [ PBIO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/27/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/27/2024 J(1) 2,872 A $0.16 33,159 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Interest on Convertible preferred stock paid in shares of common stock.
    /s/ Michael S Urdea 03/28/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

      CANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Thursday, June 20, 2024 at 4:30pm ET. Topics to be discussed include: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Status of Company's new Joint Venture Program.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 release of new nanoemulsified products, i

      6/18/24 8:16:05 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET

      SOUTH EASTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Wednesday, June 19, 2024 at 4:30 PM ET. The topics to be discussed include but are not limited to: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 commercial release of new nanoemulsified products: N

      6/13/24 10:13:34 AM ET
      $PBIO
    • Uncle Bud's Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness

      SOUTH EASTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today revealed that its wholly-owned Uncle Bud's Health & Wellness direct-to-consumer ("DTC") subsidiary ("Uncle Bud's") has announced an expansion of products and categories in 2024 to its recently formed "Premium Collection" of state-of-the-art nanoemulsified products. Premium Collection products

      4/11/24 10:52:23 AM ET
      $PBIO

    $PBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pressure BioSciences, Inc. (Amendment)

      SC 13G/A - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/30/21 2:54:00 PM ET
      $PBIO
    • SEC Form SC 13G filed by Pressure BioSciences, Inc.

      SC 13G - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/16/21 2:44:13 PM ET
      $PBIO

    $PBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      2/7/25 5:30:43 PM ET
      $PBIO
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      9/6/24 5:17:19 PM ET
      $PBIO
    • SEC Form NT 10-Q filed by Pressure BioSciences, Inc.

      NT 10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      8/19/24 5:20:09 PM ET
      $PBIO

    $PBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:23 PM ET
      $PBIO
    • Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:20 PM ET
      $PBIO
    • President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:21 PM ET
      $PBIO

    $PBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.

      SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB"). Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, inc

      2/26/24 9:06:01 AM ET
      $PBIO

    $PBIO
    Financials

    Live finance-specific insights

    See more
    • Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

      Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe

      2/5/24 8:23:04 AM ET
      $PBIO
    • Pressure BioSciences, Inc. Reports Q3 2023 Financial Results, Provides Business Update, and Offers Guidance for Remainder of 2023

      Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q3 2023 vs. Q3 2022 (rounded to nearest

      11/21/23 9:28:00 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Discuss Third Quarter 2023 Financial Results and Provide Business Update

      Conference Call Scheduled for Tuesday, November 21 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2023 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 21, 2023. Time: 4:30 PM Eastern Time (ET).To attend thi

      11/20/23 9:15:00 AM ET
      $PBIO